Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gadobenic Acid
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Crossover Comparison of MultiHance and Dotarem
Details : MultiHance (Gadobenate Dimeglumine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Diseases.
Product Name : MultiHance
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2014
Lead Product(s) : Gadobenic Acid
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadobenic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gadobenate Dimeglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peripheral Arterial Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2010
Lead Product(s) : Gadobenic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable